Company profile
Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03433027 | phase2 | completed | 2018-03-15 | 2018-12-12 | Benitec Biopharma, Inc. | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT06185673 | phase1_2 | recruiting | 2023-11-28 | 2030-11-01 | Benitec Biopharma, Inc. | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia |
FDA applications (0)
No records yet.